These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36527876)

  • 1. Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2023 Jan; 114():109555. PubMed ID: 36527876
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109331. PubMed ID: 36461591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42].
    Spadaro G; Vultaggio A; Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
    Int Immunopharmacol; 2018 Apr; 57():201. PubMed ID: 29089244
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway" [Int. Immunopharmacol. 133 (2024) 112083].
    Zhang N; Wang G; Yang L; Zhang J; Yuan Y; Ma L; Wang H; Wang Z
    Int Immunopharmacol; 2024 Jun; 134():112270. PubMed ID: 38762402
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
    Borte M; Bernatowska E; Ochs HD; Roifman CM;
    Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial" [Int. Immunopharmacol. 96 (2021) 107743].
    Sharma A; Shah M; Lakshmi S; Sane H; Captain J; Gokulchandran N; Khubchandani P; Pradeep MK; Gote P; Tuppekar B; Kulkarni P; Paranjape A; Pradhan R; Varghese R; Kasekar S; Nair V; Khanbande U
    Int Immunopharmacol; 2022 Jan; 102():107932. PubMed ID: 34274220
    [No Abstract]   [Full Text] [Related]  

  • 7. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.
    Goudouris ES; Rego Silva AM; Ouricuri AL; Grumach AS; Condino-Neto A; Costa-Carvalho BT; Prando CC; Kokron CM; Vasconcelos DM; Tavares FS; Silva Segundo GR; Barreto IC; Dorna MB; Barros MA; Forte WCN
    Einstein (Sao Paulo); 2017; 15(1):1-16. PubMed ID: 28444082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration.
    von Achenbach C; Hevia Hernandez G; von Gunten S
    Pharmacology; 2022; 107(11-12):556-563. PubMed ID: 36349790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.
    Ness S
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.
    Wasserman RL
    Immunotherapy; 2014; 6(5):553-67. PubMed ID: 24896624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.
    Bonilla FA
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):803-19, ix. PubMed ID: 18940575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig
    Kobayashi RH; Mandujano JF; Rehman SM; Kobayashi AL; Geng B; Atkinson TP; Melamed I; Turpel-Kantor E; Clodi E; Gupta S
    Immunotherapy; 2021 Jul; 13(10):813-824. PubMed ID: 33955240
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoglobulin replacement therapy for primary immunodeficiencies.
    Peter JG; Chapel H
    Immunotherapy; 2014; 6(7):853-69. PubMed ID: 25290417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.
    Canessa C; Gallo V; Pignata C; Trizzino A; Graziani S; Martire B; Moschese V; Palladino V; Boggia GM; Matucci A; Pecoraro A; Spadaro G; Vultaggio A; Azzari C
    Pediatr Allergy Immunol Pulmonol; 2019 Jun; 32(2):70-75. PubMed ID: 31508259
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "Biomimetic amphiphilic FAAP NPs nanoparticles: Synthesis, characterization and antivirus activity" [Int. Immunopharmacol. 101(Part A) (2021) 108047].
    Li X; Zhang Z; Ma X; Guo Z; Ban X; Tian Z; Zhao L; Liu Q; He Q
    Int Immunopharmacol; 2023 Sep; 122():110735. PubMed ID: 37544813
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Profiling of the pattern of the human TRB/IGH-CDR3 repertoire in primary biliary cholangitis patients" [Int. Immunopharmacol. 83 (2020) 106393].
    Han FF; Fang MX; Zhao DT; Dong YC; Yuan GH; Gao JE; Guo CL
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107063. PubMed ID: 33068861
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis" [Int. Immunopharmacol. 113(Part B) (2022) 109407].
    Chen Q; Fan K; Song G; Wang X; Zhang J; Chen H; Qin X; Lu Y; Qi W
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110941. PubMed ID: 37718175
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies.
    Borte M; Anderson-Smits C; Hermann C
    Expert Rev Clin Immunol; 2021 Apr; 17(sup1):7-8. PubMed ID: 33908818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.